Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. HOOD
6. QCOM
7. ACN
8. AZN
9. ROIV
10. AAPL

Go back to Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
TONIX PHARM HLDG (NASDAQ: TNXP) Delayed: 13.16 +0.02 (0.15%)
Previous Close $13.14    52 Week High $7.95 
Open $13.15    52 Week Low $0.40 
Day High $13.48    P/E N/A 
Day Low $12.57    EPS $-5.33 
Volume 363,365